Skip to main content

Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodine-131 Ablation

World Journal of Surgery volume 31, pages 2309–2314 (2007)Cite this article

Abstract

Aim

The aim of this study was to assess the efficacy of treatment of patients with papillary thyroid carcinoma (PTC) and lymph node metastases at the time of diagnosis and its influence on the course of the disease.

Methods

It is a retrospective review of all 51 patients with PTC and histologically proven lymph node metastases treated with I-131 ablation in our center between January 1990 and January 2003. Patients were considered disease-free if during follow-up thyroglobulin levels were undetectable and scintigraphy with 370 MBq 131I was negative during thyroid-stimulating hormone stimulation. Staging of patients was in accordance with the 5th edition of the TNM system.

Results

After a median follow-up of 84 months, 33 (65%) patients were never free of detectable disease; and 3 of these patients had died of the PTC. In total, 22 patients still showed persistent activity in the neck outside the thyroid bed, which was suspect to be cervical lymph node metastasis on postablation scintigraphy; it was not related to the initial clinical presentation (lymph node metastasis or a thyroid nodule without suspicion of metastatic disease) or to the extent of surgery. Altogether, 34 patients required additional treatment. Patients presenting with clinically overt lymph node metastasis showed a significantly (p = 0.022) lower rate of becoming disease-free than those in whom microscopic lymph node involvement was unexpectedly found upon pathologic examination. There was no significant association of the eventual outcome with the extent of surgical treatment, TNM staging, or age.

Conclusions

Patients with lymph node metastasis are considerably less likely to become disease-free. If the initial treatment does not result in a disease-free status, chances are low that additional treatment will succeed in achieving it.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Jonklaas J, Sarlis NJ, Litofsky D, et al. (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229–1242

    PubMed  Article  Google Scholar 

  2. Machens A, Hinze R, Thomusch O, et al. (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26(1):22–28

    PubMed  Article  Google Scholar 

  3. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338(5):297–306

    PubMed  Article  CAS  Google Scholar 

  4. Schlumberger MJ, Pacini F (2003) Thyroid Tumors. Paris: Editions Nucleon

    Google Scholar 

  5. Tsang RW, Brierley JD, Simpson WJ, et al. (1998) The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82(2):375–388

    PubMed  Article  CAS  Google Scholar 

  6. Travagli JP, Cailleux AF, Ricard M, et al. (1998) Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83(8):2675–2680

    PubMed  Article  CAS  Google Scholar 

  7. TNM (1997) Classification of malignant tumors. 5th edition. Berlin: Springer

    Google Scholar 

  8. de Klerk JM, de Keizer B, Zelissen PM, et al. (2000) Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Commun 21(6):529–532

    PubMed  Article  Google Scholar 

  9. de Keizer B, Koppeschaar HP, Zelissen PM, et al. (2001) Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 28(2):198–202

    PubMed  Article  CAS  Google Scholar 

  10. Verburg FA, de Keizer B, Lips CJ, et al. (2005) Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 152(1):33–37

    PubMed  Article  CAS  Google Scholar 

  11. Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6):947–953

    PubMed  CAS  Google Scholar 

  12. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428

    PubMed  Article  CAS  Google Scholar 

  13. Sherman SI, Brierley JD, Sperling M, et al. (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome: National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012–1021

    PubMed  Article  CAS  Google Scholar 

  14. Simpson WJ, McKinney SE, Carruthers JS, et al. (1987) Papillary and follicular thyroid cancer: prognostic factors in 1,578 patients. Am J Med 83(3):479–488

    PubMed  Article  CAS  Google Scholar 

  15. Beasley NJP, Lee J, Eski S, et al. (2002) Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 128(7):825–828

    PubMed  Google Scholar 

  16. Noguchi M, Earashi M, Kitagawa H, et al. (1992) Papillary thyroid cancer and its surgical management. J Surg Oncol 49(3):140–146

    PubMed  Article  CAS  Google Scholar 

  17. Scheumann GF, Gimm O, Wegener G, et al. (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18(4):559–567

    PubMed  Article  CAS  Google Scholar 

  18. DeGroot LJ, Kaplan EL, McCormick M, et al. (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71(2):414–424

    PubMed  CAS  Article  Google Scholar 

  19. McConahey WM, Hay ID, Woolner LB, et al. (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61(12):978–996

    PubMed  CAS  Google Scholar 

  20. Hughes CJ, Shaha AR, Shah JP, et al. (1996) Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18(2):127–132

    PubMed  Article  CAS  Google Scholar 

  21. Leboulleux S, Rubino C, Baudin E, et al. (2005) Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90(10):5723–5729

    PubMed  Article  CAS  Google Scholar 

  22. Sugitani I, Kasai N, Fujimoto Y, et al. (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135(2):139–148

    PubMed  Article  Google Scholar 

  23. Anonymous (2002) Classification of Malignant Tumors. 6th edition. New York: Wiley-Liss

  24. Salvatori M, Rufini V, Reale F, et al. (2003) Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. World J Surg 27(7):770–775

    PubMed  Article  Google Scholar 

  25. Gulec SA, Eckert M, Woltering EA (2002) Gamma probe-guiolced lymph node dissection (′gamma picking) in differentiated thyroid carcinoma. Clin Nucl Med 27(12):859–861

    PubMed  Article  Google Scholar 

  26. Pereira JA, Jimeno J, Miquel J, et al. (2005) Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138(6):1095–1100

    PubMed  Article  Google Scholar 

  27. Pak H, Gourgiotis L, Chang WI, et al. (2003) Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol 82(1):10–18

    PubMed  Article  Google Scholar 

  28. Pacini F, Cetani F, Miccoli P, et al. (1994) Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 18(4):600–604

    PubMed  Article  CAS  Google Scholar 

  29. Solans R, Bosch JA, Galofre P, et al. (2001) Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42(5):738–743

    PubMed  CAS  Google Scholar 

  30. Kloos RT, Duvuuri V, Jhiang SM, et al. (2002) Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87(12):5817–5820

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Frederik A. Verburg

    Present address: Department of Nuclear Medicine, University Hospital Würzburg, Josef Schneiderstrasse 2, Bau D5, 97080, Würzburg, Germany

Affiliations

  1. Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

    Frederik A. Verburg, Bart de Keizer, Marnix G. E. H. Lam, J. M. H. de Klerk & Johannes W. van Isselt

  2. Department of Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands

    Cornelis J. M. Lips

  3. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands

    Inne H. M. Borel-rinkes

  4. Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands

    J. M. H. de Klerk

Authors
  1. Frederik A. Verburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bart de Keizer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marnix G. E. H. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. M. H. de Klerk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cornelis J. M. Lips
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Inne H. M. Borel-rinkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johannes W. van Isselt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederik A. Verburg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Verburg, F.A., de Keizer, B., Lam, M.G.E.H. et al. Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodine-131 Ablation. World J Surg 31, 2309–2314 (2007). https://doi.org/10.1007/s00268-007-9257-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-007-9257-2

Keywords

  • Papillary Thyroid Carcinoma
  • Thyroid Nodule
  • Persistent Disease
  • 131I Therapy
  • Thyroglobulin Level